Get the Stockscreener App
0.7056
4.72%
0.0356
Coherus Biosciences Inc stock is traded at $0.7056, with a volume of 1.22M.
It is up +4.72% in the last 24 hours and down -32.54% over the past month.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
See More
Previous Close:
$0.67
Open:
$0.6603
24h Volume:
1.22M
Relative Volume:
0.54
Market Cap:
$83.34M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.2125
EPS:
-3.32
Net Cash Flow:
$-175.17M
1W Performance:
-5.62%
1M Performance:
-32.54%
6M Performance:
-69.09%
1Y Performance:
-80.57%
1-Day Range:
$0.6603
$0.7259
1-Week Range:
$0.6603
$0.7785
52-Week Range:
$0.6603
$3.73
Coherus Biosciences Inc Stock (CHRS) Company Profile
Name
Coherus Biosciences Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Biosciences Inc Stock (CHRS) Latest News
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to K - GuruFocus.com
CHRS stock touches 52-week low at $0.71 amid market challenges - Investing.com
Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CHRS stock plunges to 52-week low, hitting $0.79 By Investing.com - Investing.com Canada
CHRS stock plunges to 52-week low, hitting $0.79 - Investing.com India
Warning: CHRS is at high risk of performing badly - MSN
Such Is The Power Of Coherus Biosciences Inc (NASDAQ: CHRS) - Stocks Register
Coherus BioSciences (NASDAQ:CHRS) Lowered to "Hold" at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.85 amid market challenges - Investing.com India
CHRS stock touches 52-week low at $0.85 amid market challenges By Investing.com - Investing.com South Africa
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest - MarketBeat
How should investors view Coherus Biosciences Inc (CHRS)? - US Post News
Coherus Biosciences Inc Inc. (CHRS) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
StockNews.com Upgrades Coherus BioSciences (NASDAQ:CHRS) to “Buy” - Defense World
Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight - The Dwinnex
AQR Capital Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
719,999 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by AQR Capital Management LLC - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Biosciences Inc (CHRS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Coherus cancer drug undercuts Merck's Keytruda - MSN
Coherus Biosciences Inc (CHRS) is looking forward to a strong quarter - SETE News
How will Coherus Biosciences Inc’s (CHRS) earnings compare to estimates this quarter? - US Post News
Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now - Insider Monkey
Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges By Investing.com - Investing.com South Africa
Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges - Investing.com
Junshi wins European approval for cheaper checkpoint blocker - The Pharma Letter
Coherus Biosciences Inc [CHRS] President & CEO makes an insider purchase of 223,100 shares worth 0.45 million. - Knox Daily
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Insider Monkey
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive - Simply Wall St
CHRS (Coherus BioSciences) Debt-to-EBITDA : -10.54 (As of Jun. 2024) - GuruFocus.com
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses - Yahoo Finance
HC Wainwright Weighs in on Coherus BioSciences, Inc.'s FY2028 Earnings (NASDAQ:CHRS) - MarketBeat
Coherus shares stumble on supply issue - The Pharma Letter
Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Australia
Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St
Baird maintains Coherus outperform stock rating on recent supply hiccup - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat
Coherus BioSciences faces UDENYCA supply disruption - Investing.com India
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Downgraded to "Hold" at StockNews.com - MarketBeat
Coherus Biosciences Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Coherus Biosciences Inc Stock (CHRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lanfear Dennis M | President & CEO |
Nov 22 '23 |
Option Exercise |
1.42 |
299,940 |
425,015 |
954,793 |
| Lanfear Dennis M | President & CEO |
Nov 22 '23 |
Sale |
2.02 |
223,100 |
449,770 |
731,693 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):